# The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

> **NCT01319331** · PHASE1 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 12 (actual)

## Conditions studied

- Diabetes
- Type 1 Diabetes

## Interventions

- **DRUG:** Alpha 1-Antitrypsin (AAT, Aralast NP)

## Key facts

- **NCT ID:** NCT01319331
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2015-10
- **Final completion:** 2016-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01319331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01319331, "The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01319331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*